Episode 11. Christopher Heath Wellman on Immigration

There is no denying that international borders—coercively upheld and protected—are a huge factor in determining the distribution of wealth and opportunities throughout the world. From education and health care, to access to credit and the rule of law, a host of factors that influence quality of life depend simply on which side of a border a person is born on. Yet what could be more arbitrary, morally speaking, than where a person happens to be born? And why is it that inequality and poverty traceable back to this factor is generally considered less objectionable than deprivations that result from factors such as race, ethnicity or gender?

To get a grip on these questions, Public Ethics Radio discussed immigration and citizenship policies with Christopher Heath Wellman. Wellman is Professor of Philosophy at Washington University in St. Louis, and a Professorial Research Fellow at Charles Sturt University in the Centre for Applied Philosophy and Public Ethics, an Australian Research Council Special Research Centre. His views on immigration are also set out in his recent, “Immigration and Freedom of Association,” Ethics 119, no. 1 (2008): 109–141.

Episode 9. Michael Selgelid on Infectious Diseases

Can we infringe individual rights to promote public health? Should, say, individuals be allowed to determine for themselves when they are too infectious to get on a plane? What happens when an individual contracts a new disease that is of unknown virulence? How do we deal with patients who don’t take their prescriptions correctly and risk allowing dangerous pathogens to mutate?

These urgent questions are the domain of the bioethics of infectious disease. On this episode of Public Ethics Radio, we are aided in the search for answers by the philosopher and tuberculosis expert Michael Selgelid.

Announcing a Public Ethics column

Here’s something to keep you busy between PER episodes. Christian and I are going to start writing a regular column in the online magazine Policy Innovations. It’ll be called the Public Ethicist–or something like that. We’re still working out the details.

Our pilot article is up there now. We take a look at pharma giant GlaxoSmithKline’s decision to cut some prices in developing countries. Check it out and let us know what you think.